Saving lives with accurate HER2 testing

American Journal of Clinical Pathology

Volumn 134, Issue 2, 2010, Pages 183-184

  Jeffrey S, Ross ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; TRASTUZUMAB;

ADJUVANT CHEMOTHERAPY; ASSAY; BREAST CANCER; CANCER INCIDENCE; CANCER SCREENING; CANCER THERAPY; DEATH; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; EDITORIAL; FALSE POSITIVE RESULT; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IMMUNOHISTOCHEMISTRY; LIFE; METASTASIS; PATHOLOGIST; PRIORITY JOURNAL; QUALITY CONTROL;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; RECEPTOR, ERBB-2;

EID: 77955621175     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCP6VZ8YHMZNNED     Document Type: Editorial

References (7)

1. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-792. (Pubitemid 32222155)
2. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355:2733-2743. (Pubitemid 46021510)
3. Ross JS, Slodkowska EA, Symmans WF, et al. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist. 2009;14:320-368.
4. Grimm E, Schmidt R, Swanson P, et al. Achieving 95% cross-methodological concordance in HER2 testing: causes and implications of discordant cases. Am J Clin Pathol. 2010;134:284-292.
5. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118-145.
6. Chien AJ, Rugo HS. The cardiac safety of trastuzumab in the treatment of breast cancer. Expert Opin Drug Saf. 2010;9:335-346.
7. Paik S, Kim C, Wolmark N. HER2 status and benefit from adjuvant trastuzumab in breast cancer [letter]. N Engl J Med. 2008;358:1409-1411. (Pubitemid 351468442)